Outlook Therapeutics Inc. (OTLK)
OTLK Stock Up 35% as FDA Accepts Resubmitted Eye Drug BLA for Review
Outlook Therapeutics stock surges 35% after the FDA accepts the resubmitted Lytenava BLA for wet AMD for review, setting a July 29, 2026, decision date.
Oncobiologics, Inc. (OTLK) Reports Q2 Loss, Lags Revenue Estimates
Oncobiologics, Inc. (OTLK) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to a loss of $0.4 per share a year ago.
Oncobiologics, Inc. (OTLK) Reports Q1 Loss, Misses Revenue Estimates
Oncobiologics, Inc. (OTLK) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.89 per share a year ago.
OTLK Stock Crashes 67% in a Week: Here's What You Need to Know
Outlook Therapeutics stock plunges 67% in a week after the FDA issues a third CRL rejecting its ONS-5010 BLA for wet AMD, again seeking confirmatory data.
US FDA declines to approve Outlook Therapeutics' eye disease drug
The U.S. Food and Drug Administration has declined to approve Outlook Therapeutics' drug for a type of eye disease, the company said on Wednesday, marking another setback to its prolonged effort to bring the treatment to market.
Third Time's The Charm: Outlook Therapeutics Lytenava Heads To FDA, Again
Outlook Therapeutics (OTLK) faces a pivotal FDA decision for Lytenava on December 31st, following two prior rejections and a 2025 recovery in share price. My bullish stance is underpinned by the NORSE EIGHT trial, conducted under Special Protocol Assessment, and improved manufacturing controls addressing prior FDA concerns. OTLK reported initial Lytenava revenues in Europe, but maintains a high cash burn, with roughly four months of runway and a $139M enterprise value.
Oncobiologics, Inc. (OTLK) Reports Q4 Loss, Lags Revenue Estimates
Oncobiologics, Inc. (OTLK) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to a loss of $0.77 per share a year ago.
OTLK Stock Crashes 54% as FDA Issues Second CRL for Eye Disease Drug
Outlook Therapeutics stock plunges 54% after the FDA rejects ONS-5010 BLA again, citing lack of efficacy data in confirmatory study.
Outlook Therapeutics: Why The Odds Point To A Favorable FDA Decision
FDA approval for Lytenava might come next week, I see Outlook Therapeutics at a pivotal inflection point, offering a rare asymmetric risk/reward setup. Lytenava's European approval, decade-long exclusivity, and initial sales validate its regulatory and commercial path, providing a strong foundation for US launch. Financials are tight, cash burn is high, and revenue is minimal, but US approval could rapidly shift the outlook, unlocking a much larger market.
Oncobiologics, Inc. (OTLK) Reports Q3 Loss, Lags Revenue Estimates
Oncobiologics, Inc. (OTLK) came out with a quarterly loss of $0.44 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to a loss of $0.83 per share a year ago.
OTLK Stock Falls on Failure to Meet Non-Inferiority Goal in AMD Study
Outlook Therapeutics stock tanks 65% as ONS-5010 fails to meet the pre-specified non-inferiority endpoint at week 8 in the 90-day NORSE EIGHT study for wet AMD.
Why Is Eye Disease-Focused Outlook Therapeutics Stock Trading Lower On Wednesday?
Outlook Therapeutics Inc. OTLK revealed preliminary topline results of NORSE EIGHT, the second of two clinical trials evaluating ONS-5010 in wet AMD patients.
